Just last Friday 16th February 2024, the FDA gave yet another blessing to Tagrisso, AstraZeneca’s mega-blockbuster for EGFR-mutant Non-small Cell […]

Programmed death ligand 1 (PD-L1) expression is recognized as a key biomarker in the treatment of non–small cell lung cancer […]

This appropriately designed study compared two dose levels of enobosarm in patients with ER+, HER2-, and AR+ advanced breast cancer.  […]

Cervical cancer is the 4th most common cancer in women and the 4th most common cause of death from cancer […]

Immunotherapy has become one of the most widely used interventions for treating patients with cancer and continues to be a […]

Radium-223 and taxane chemotherapy each improve survival of patients with metastatic castration-resistant prostate cancer (mCRPC). Whether the radium-223–taxane sequence could […]

A study published today in Nature Medicine highlights how the use of biomarkers to guide targeted therapy combined with immunotherapy […]

Accurate clinical staging of localised pancreatic ductal adenocarcinoma (and indeed any cancer ) is absolutely crucial to receiving the right […]

This is a large retrospective international of 225-Ac PSMA conducted in 488 men with pretreated mCRPC. Median OS was 15.5 […]

The use of immune checkpoint inhibitors (ICIs) has revolutionized cancer care, particularly in immune-inflamed tumors and tumors with a high […]